Drug · Monoclonal Antibody
Rituximab
CI-DRUG-00000703Explore in graph →CHEMBL1201576 Approved
Regulatory
Approvals (37)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as RIABNI (DIN 02513447) under ATC L01FA01 RITUXIMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Oct 10, 2024 | Apr 21, 2021 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as RUXIENCE (DIN 02495724) under ATC L01FA01 RITUXIMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | May 26, 2020 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as RIXIMYO (DIN 02498316) under ATC L01FA01 RITUXIMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | May 22, 2020 |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 14 hours agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 4 | 334 | 143 | 247 | 1,358 | 37 | CA, EU, US | Nov 26, 1997 | May 8, 1993 |
| Non-Hodgkin Lymphoma | Approved | Phase 4 | 226 | 94 | 148 | 743 | 2 | EU, US | Nov 26, 1997 | May 8, 1993 |
| Leukemia | Phase4 | Phase 4 | 60 | 29 | 44 | 307 | 0 | — | — | 1997-09 |
| Malignant Central Nervous System Neoplasm | Phase3 | Phase 3 | 16 | 10 | 1 | 35 | 0 |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (1,384)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01902862 | An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma | terminated | Phase 2 | 7 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Apr 1, 2014 | clinicaltrials |
| NCT00556699 | A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma |